Novartis Cash and Equivalents

NVS -- USA Stock  

Fiscal Quarter End: December 31, 2019  

Novartis cash-and-equivalents fundamental analysis lookup allows you to check this and other indicators for Novartis AG or any other equity instrument. You can also select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please check also Equity Screeners to view more equity screening tools

Novartis Cash and Equivalents Analysis

Cash or Cash Equivalents are the most liquid of all assets found on company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Bank Deposits 
More About Cash and Equivalents | All Equity Analysis
Novartis Cash and Equivalents  =
8.63 B
Novartis ValuationFundamentalsBuy or Sell

Novartis Cash and Equivalents Over Time Pattern

 Novartis Cash and Equivalents 

About Cash and Equivalents

Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually 3 months).
Compare to competition
Consolidated Income
In accordance with recently published financial statements Novartis AG has 8.63 B in Cash and Equivalents. This is 951.32% higher than that of the Healthcare sector, and significantly higher than that of Drug Manufacturers?General industry, The Cash and Equivalents for all stocks is 219.38% lower than the firm.

Novartis Cash and Equivalents Peer Comparison

  Cash and Equivalents 
      Novartis Comparables 
Novartis is regarded fifth in cash and equivalents category among related companies.

Novartis current financial ratios